UNC93B1 and acute myeloid leukemia: Furthermore, we rationally proposed UNC93B1 level can also distinctly reflect survival outcomes of different subgroups, and the analysis showed higher UNC93B1 level had a more pronounced shortens of survival in AML patients with older age (age > 60, HR: 10.98, p = 0.021, Figure 2B), non-M3 FAB subtype (HR: 1.90, p = 0.004, Figure 2C), WBC counts in peripheral blood ≤ 20 x10^9/L (HR: 2.76, p = 0.001, Figure 2D), and unfavorable cytogenetic risk (including Intermediate cytogenetic risk and Poor cytogenetic risk, HR = 2.49, p = 0.001, Figure 2E).